[Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization (TAE)--significance of repetitive therapies and responses to them within 6 months after the first intervention].
We retrospectively analyzed the prognostic factors associated with survival in HCC patients (113 cases, male 95, female 18, mean age 62.1 +/- 8.2yr.) treated only by TAE. Univariate analysis revealed that following factors significantly correlated with survival, such as T.Bil, tumor type, Vp factor, the response to the first TAE and the best response to TAE attained within 6 months after the first therapy. Also, multivariate analysis proved that T.Bil, ICGR15' and the best response to TAE during the initial 6 months were significant. Even if the first response to TAE was "no-change (NC)", the cumulative survival rate of patients would be improved when the responses to the second or the third therapy became "partial response (PR)" within 6 months after the first one. There were no significant differences between patients with which the best response to TAE within the initial 6 months were PR and those with NC in clinical backgrounds, dose of anti-cancer drugs, and dose of lipiodol used in the therapies. However, the mean interval between the first and the second TAE performed within 6 months 70 days. These results implied the importance of getting "PR" state no later than 6 months after the first intervention for the long survival in HCC patients. To accomplish this, repetitive treatments between short periods were recommended.
Kantoh
T
T
Department of Internal Medicine, Sakai Municipal Hospital.
Abo
H
H
Tomotsu
K
K
Usui
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D011379:Prognosis; D012044:Regression Analysis; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
D015251:Epirubicin; D016685:Mitomycin; D007459:Iodized Oil; D004317:Doxorubicin